# Hypotension & Hemorrhage â€“ RRT Protocol with Virtua Voorhees Addenda

**Primary Guideline:** American College of Surgeons Committee on Trauma (ACS-COT) Advanced Trauma Life Support (ATLS) 2022
**Official Source:** https://www.facs.org/quality-programs/trauma/atls/
**Supporting Guidelines:**
- European Society of Anaesthesiology and Intensive Care (ESAIC) Guidelines on Management of Severe Perioperative Bleeding 2023
- Society of Critical Care Medicine (SCCM) Surviving Sepsis Campaign 2021

## ENHANCED MERMAID FLOWCHART ALGORITHM

~~~mermaid
graph TD
    A["Hypotension Recognition<br/>MAP <65 or SBP <90"] --> B["Initial Stabilization<br/>IV Access + O2 + Monitors"]
    
    B --> C["Fluid Resuscitation<br/>30 mL/kg Crystalloid Bolus"]
    
    C --> D{"Signs of Active<br/>Hemorrhage?"}
    
    D -->|YES| E["Activate MTP<br/>Control Bleeding"]
    D -->|NO| F["Evaluate Non-hemorrhagic<br/>Shock Etiology"]
    
    E --> G["Blood Products<br/>1:1:1 Ratio"]
    F --> H{"Fluid<br/>Responsive?"}
    
    G --> I{"Bleeding<br/>Controlled?"}
    H -->|YES| J["Continue Fluids<br/>Monitor Response"]
    H -->|NO| K["Vasopressor Support<br/>Identify Shock Type"]
    
    I -->|NO| L["Surgical/IR Intervention<br/>Source Control"]
    I -->|YES| M["Coagulopathy Correction<br/>Hemostasis Optimization"]
    
    K --> N{"Shock Type<br/>Classification"}
    
    N -->|DISTRIBUTIVE| O["Antibiotics + Cultures<br/>Source Control"]
    N -->|CARDIOGENIC| P["Inotropes + Echo<br/>Consider MCS"]
    N -->|HYPOVOLEMIC| Q["Volume Replacement<br/>Source Identification"]
    N -->|OBSTRUCTIVE| R["Remove Obstruction<br/>Decompress/Anticoag"]
    
    L --> S["ICU Monitoring<br/>Ongoing Resuscitation"]
    M --> S
    O --> S
    P --> T["ECMO Evaluation<br/>Refractory Shock"]
    Q --> S
    R --> S
    J --> S
    
    T --> U["Mobile ECMO<br/>Transfer Center"]
    U --> V["ECMO Cannulation<br/>Advanced Support"]
    
    style A fill:#ffcccc
    style B fill:#ffe6cc
    style E fill:#fff2cc
    style G fill:#ccffcc
    style L fill:#ffaaaa
    style P fill:#e6ccff
    style S fill:#ccffee
~~~

## STREAMLINED DYNAMIC CARD SYSTEM

### Card 0 â€“ Hypotension Recognition & Initial Stabilization (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ HYPOTENSION RRT ACTIVATION            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Recognition criteria:                â”‚
â”‚ â€¢ MAP <65 mmHg or SBP <90 mmHg         â”‚
â”‚ â€¢ Signs of hypoperfusion               â”‚
â”‚ â€¢ Shock index >1.0                     â”‚
â”‚ â€¢ Oliguria <0.5 mL/kg/hr               â”‚
â”‚                                         â”‚
â”‚ ğŸš€ Immediate actions (<5 minutes):      â”‚
â”‚ â€¢ High-flow oxygen if needed           â”‚
â”‚ â€¢ Large-bore IV access Ã— 2 (â‰¥18G)      â”‚
â”‚ â€¢ Continuous monitoring                â”‚
â”‚ â€¢ Baseline vital signs                 â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Essential labs:                      â”‚
â”‚ â€¢ CBC, BMP, lactate                    â”‚
â”‚ â€¢ PT/INR, PTT, fibrinogen              â”‚
â”‚ â€¢ Type & crossmatch                    â”‚
â”‚ â€¢ ABG if indicated                     â”‚
â”‚                                         â”‚
â”‚ [Next: Fluid resuscitation â–¶]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1A â€“ Fluid Resuscitation (Node C â†’ D)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’§ INITIAL FLUID RESUSCITATION          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Fluid challenge protocol:            â”‚
â”‚ â€¢ 30 mL/kg crystalloid bolus           â”‚
â”‚ â€¢ Balanced solutions preferred         â”‚
â”‚ â€¢ Warm fluids if available             â”‚
â”‚ â€¢ Rapid infusion (<30 minutes)         â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Response assessment markers:         â”‚
â”‚ â€¢ Blood pressure improvement           â”‚
â”‚ â€¢ Heart rate reduction                 â”‚
â”‚ â€¢ Improved mental status               â”‚
â”‚ â€¢ Increased urine output               â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Monitor for fluid overload:          â”‚
â”‚ â€¢ Pulmonary edema                      â”‚
â”‚ â€¢ JVD elevation                        â”‚
â”‚ â€¢ Decreased oxygen saturation          â”‚
â”‚                                         â”‚
â”‚ [Next: Hemorrhage assessment â–¶]        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Recognition]              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ Hemorrhage Assessment (Node D)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©¸ ACTIVE HEMORRHAGE EVALUATION          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ” Clinical signs of bleeding:          â”‚
â”‚ â€¢ Obvious external bleeding            â”‚
â”‚ â€¢ Hematemesis, melena, hematochezia    â”‚
â”‚ â€¢ Abdominal distension/rigidity        â”‚
â”‚ â€¢ Retroperitoneal hematoma signs       â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Laboratory indicators:               â”‚
â”‚ â€¢ Dropping hemoglobin trend            â”‚
â”‚ â€¢ Rising lactate levels                â”‚
â”‚ â€¢ Coagulopathy (â†‘PT/INR)               â”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Diagnostic tools:                    â”‚
â”‚ â€¢ FAST ultrasound examination          â”‚
â”‚ â€¢ Nasogastric tube if upper GI         â”‚
â”‚ â€¢ Recent procedure review              â”‚
â”‚ â€¢ Anticoagulation history              â”‚
â”‚                                         â”‚
â”‚ â“ Active hemorrhage suspected?         â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Activate MTP                  â”‚
â”‚ ğŸ”˜ NO â†’ Non-hemorrhagic evaluation     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ Massive Transfusion Protocol (Node E â†’ G)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ MASSIVE TRANSFUSION ACTIVATION       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Blood bank activation:               â”‚
â”‚ â€¢ Call blood bank immediately          â”‚
â”‚ â€¢ Request MTP pack activation          â”‚
â”‚ â€¢ Rapid release of O-negative blood    â”‚
â”‚                                         â”‚
â”‚ ğŸ©¸ Initial bleeding control:            â”‚
â”‚ â€¢ Direct pressure to bleeding sites    â”‚
â”‚ â€¢ Tourniquet application if appropriateâ”‚
â”‚ â€¢ Hemostatic agents as available       â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Pharmacologic interventions:         â”‚
â”‚ â€¢ Tranexamic acid 1g IV (if <3 hours)  â”‚
â”‚ â€¢ Calcium chloride 1g IV               â”‚
â”‚ â€¢ Consider factor concentrates         â”‚
â”‚                                         â”‚
â”‚ [Next: Blood product administration â–¶] â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Hemorrhage Assessment]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3B â€“ Non-hemorrhagic Evaluation (Node F â†’ H)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ” NON-HEMORRHAGIC SHOCK ASSESSMENT     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ©º Clinical evaluation:                 â”‚
â”‚ â€¢ Temperature (sepsis screening)       â”‚
â”‚ â€¢ Heart sounds (murmurs, rubs)         â”‚
â”‚ â€¢ Lung examination (crackles, wheeze)  â”‚
â”‚ â€¢ Extremity perfusion assessment       â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Diagnostic workup:                   â”‚
â”‚ â€¢ 12-lead ECG (STEMI, arrhythmia)      â”‚
â”‚ â€¢ Chest X-ray (pneumothorax, edema)    â”‚
â”‚ â€¢ Echocardiogram (function, tamponade) â”‚
â”‚ â€¢ Lactate and base deficit             â”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Additional testing:                  â”‚
â”‚ â€¢ Blood cultures if febrile            â”‚
â”‚ â€¢ Urinalysis and culture               â”‚
â”‚ â€¢ D-dimer if PE suspected              â”‚
â”‚                                         â”‚
â”‚ [Next: Fluid responsiveness test â–¶]    â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Hemorrhage Assessment]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Blood Product Administration (Node G â†’ I)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©¸ BLOOD PRODUCT RESUSCITATION          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ MTP ratios (1:1:1 preferred):        â”‚
â”‚ â€¢ PRBCs: Target Hgb >7 g/dL            â”‚
â”‚ â€¢ FFP: Correct coagulopathy (INR <1.5) â”‚
â”‚ â€¢ Platelets: Maintain >50,000/ÂµL       â”‚
â”‚ â€¢ Cryoprecipitate: If fibrinogen <150  â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring parameters:               â”‚
â”‚ â€¢ Hemoglobin levels q30min             â”‚
â”‚ â€¢ Coagulation studies q1h              â”‚
â”‚ â€¢ Platelet count trending              â”‚
â”‚ â€¢ Fibrinogen levels                    â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Complications to monitor:            â”‚
â”‚ â€¢ Transfusion reactions                â”‚
â”‚ â€¢ Hypothermia from blood products      â”‚
â”‚ â€¢ Electrolyte abnormalities           â”‚
â”‚                                         â”‚
â”‚ [Next: Bleeding control assessment â–¶]  â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: MTP Activation]           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ Fluid Responsiveness Assessment (Node H)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š FLUID RESPONSIVENESS EVALUATION      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Response indicators:                 â”‚
â”‚ â€¢ SBP increase >10 mmHg                â”‚
â”‚ â€¢ HR decrease >10 bpm                  â”‚
â”‚ â€¢ Improved mental status               â”‚
â”‚ â€¢ Urine output >0.5 mL/kg/hr           â”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Advanced assessment:                 â”‚
â”‚ â€¢ Passive leg raise test               â”‚
â”‚ â€¢ IVC diameter on ultrasound           â”‚
â”‚ â€¢ Pulse pressure variation             â”‚
â”‚ â€¢ Stroke volume variation              â”‚
â”‚                                         â”‚
â”‚ â“ Fluid responsive?                    â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Continue fluid resuscitation  â”‚
â”‚ ğŸ”˜ NO â†’ Vasopressor support needed     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6A â€“ Bleeding Control Assessment (Node I)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”„ BLEEDING CONTROL EVALUATION          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Success indicators:                  â”‚
â”‚ â€¢ Stable hemoglobin levels             â”‚
â”‚ â€¢ Decreased blood product requirements â”‚
â”‚ â€¢ Hemodynamic stabilization           â”‚
â”‚ â€¢ Reduced active bleeding signs        â”‚
â”‚                                         â”‚
â”‚ ğŸš¨ Continued bleeding signs:            â”‚
â”‚ â€¢ Ongoing hemoglobin drop              â”‚
â”‚ â€¢ Persistent hypotension               â”‚
â”‚ â€¢ Increasing abdominal girth           â”‚
â”‚ â€¢ Fresh blood from wounds/orifices     â”‚
â”‚                                         â”‚
â”‚ â“ Bleeding adequately controlled?      â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Coagulopathy correction       â”‚
â”‚ ğŸ”˜ NO â†’ Surgical/IR intervention       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7A â€“ Vasopressor Support (Node K â†’ N)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’Š VASOPRESSOR THERAPY                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ First-line therapy:                  â”‚
â”‚ â€¢ Norepinephrine 0.05-3 mcg/kg/min     â”‚
â”‚ â€¢ Target MAP â‰¥65 mmHg                  â”‚
â”‚ â€¢ Central line preferred               â”‚
â”‚                                         â”‚
â”‚ ğŸ”„ Escalation options:                  â”‚
â”‚ â€¢ Vasopressin 0.03-0.04 units/min      â”‚
â”‚ â€¢ Epinephrine 0.05-2 mcg/kg/min        â”‚
â”‚ â€¢ Dopamine 5-20 mcg/kg/min             â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring requirements:             â”‚
â”‚ â€¢ Arterial line placement              â”‚
â”‚ â€¢ Central venous access                â”‚
â”‚ â€¢ Continuous cardiac monitoring        â”‚
â”‚                                         â”‚
â”‚ [Next: Shock type classification â–¶]    â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Fluid Response]           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8A â€“ Surgical/IR Intervention (Node L â†’ S)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”ª URGENT SURGICAL INTERVENTION         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Immediate consultations:             â”‚
â”‚ â€¢ General surgery                      â”‚
â”‚ â€¢ Interventional radiology             â”‚
â”‚ â€¢ Anesthesia for OR                    â”‚
â”‚ â€¢ Blood bank coordination              â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Source control priorities:           â”‚
â”‚ â€¢ Damage control surgery               â”‚
â”‚ â€¢ Embolization procedures              â”‚
â”‚ â€¢ Endoscopic interventions             â”‚
â”‚ â€¢ Balloon tamponade devices            â”‚
â”‚                                         â”‚
â”‚ ğŸ¥ Preparation requirements:            â”‚
â”‚ â€¢ OR availability assessment           â”‚
â”‚ â€¢ Anesthesia team activation           â”‚
â”‚ â€¢ Continue blood product support       â”‚
â”‚                                         â”‚
â”‚ [Next: ICU monitoring â–¶]               â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Bleeding Control]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8B â€“ Shock Type Classification (Node N)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ” SHOCK TYPE IDENTIFICATION            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¦  Distributive shock indicators:        â”‚
â”‚ â€¢ Fever or hypothermia                 â”‚
â”‚ â€¢ Infection source identified          â”‚
â”‚ â€¢ High cardiac output, low SVR         â”‚
â”‚ â€¢ Warm, vasodilated extremities        â”‚
â”‚                                         â”‚
â”‚ ğŸ’“ Cardiogenic shock indicators:         â”‚
â”‚ â€¢ Low cardiac output                   â”‚
â”‚ â€¢ Elevated JVD                         â”‚
â”‚ â€¢ Pulmonary edema                      â”‚
â”‚ â€¢ ECG changes suggesting MI            â”‚
â”‚                                         â”‚
â”‚ ğŸ« Obstructive shock indicators:         â”‚
â”‚ â€¢ Sudden onset                        â”‚
â”‚ â€¢ Signs of PE, pneumothorax            â”‚
â”‚ â€¢ Beck's triad (tamponade)             â”‚
â”‚                                         â”‚
â”‚ â“ Primary shock type identified?       â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ DISTRIBUTIVE â†’ Antibiotic therapy   â”‚
â”‚ ğŸ”˜ CARDIOGENIC â†’ Inotropic support     â”‚
â”‚ ğŸ”˜ OBSTRUCTIVE â†’ Remove obstruction    â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9A â€“ Distributive Shock Management (Node O â†’ S)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¦  DISTRIBUTIVE SHOCK TREATMENT          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Antimicrobial therapy:               â”‚
â”‚ â€¢ Broad-spectrum antibiotics <1 hour   â”‚
â”‚ â€¢ Culture-guided therapy when availableâ”‚
â”‚ â€¢ Source control evaluation            â”‚
â”‚                                         â”‚
â”‚ ğŸ” Infection source control:            â”‚
â”‚ â€¢ Remove infected devices              â”‚
â”‚ â€¢ Drain abscesses                      â”‚
â”‚ â€¢ Debride necrotic tissue              â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Sepsis monitoring:                   â”‚
â”‚ â€¢ Lactate clearance >10% in 2 hours    â”‚
â”‚ â€¢ ScvO2 >70% goal                      â”‚
â”‚ â€¢ Procalcitonin trending               â”‚
â”‚                                         â”‚
â”‚ [Next: ICU monitoring â–¶]               â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Shock Classification]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9B â€“ Cardiogenic Shock Management (Node P â†’ T)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’“ CARDIOGENIC SHOCK TREATMENT           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Inotropic support:                   â”‚
â”‚ â€¢ Dobutamine 2.5-20 mcg/kg/min         â”‚
â”‚ â€¢ Milrinone 0.125-0.75 mcg/kg/min      â”‚
â”‚ â€¢ Avoid excessive preload reduction    â”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Diagnostic evaluation:               â”‚
â”‚ â€¢ Echocardiogram (function, structure) â”‚
â”‚ â€¢ 12-lead ECG (STEMI evaluation)       â”‚
â”‚ â€¢ Coronary angiography if indicated    â”‚
â”‚                                         â”‚
â”‚ ğŸ› ï¸ Mechanical support consideration:    â”‚
â”‚ â€¢ IABP for appropriate candidates       â”‚
â”‚ â€¢ Impella for severe LV dysfunction    â”‚
â”‚ â€¢ VA-ECMO for refractory shock         â”‚
â”‚                                         â”‚
â”‚ [Next: ECMO evaluation â–¶]              â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Shock Classification]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9C â€“ Obstructive Shock Management (Node R â†’ S)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ« OBSTRUCTIVE SHOCK TREATMENT           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Cause-specific interventions:        â”‚
â”‚                                         â”‚
â”‚ ğŸ’¨ Tension pneumothorax:                â”‚
â”‚ â€¢ Immediate needle decompression       â”‚
â”‚ â€¢ Chest tube placement                 â”‚
â”‚                                         â”‚
â”‚ ğŸ«€ Cardiac tamponade:                   â”‚
â”‚ â€¢ Emergent pericardiocentesis          â”‚
â”‚ â€¢ Surgical window if needed            â”‚
â”‚                                         â”‚
â”‚ ğŸ« Massive pulmonary embolism:          â”‚
â”‚ â€¢ Anticoagulation if no bleeding       â”‚
â”‚ â€¢ Thrombolysis consideration           â”‚
â”‚ â€¢ Embolectomy evaluation               â”‚
â”‚                                         â”‚
â”‚ [Next: ICU monitoring â–¶]               â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Shock Classification]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 10A â€“ ECMO Evaluation (Node T â†’ U)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”¬ ECMO CANDIDATE ASSESSMENT            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… Inclusion criteria:                  â”‚
â”‚ â€¢ Refractory cardiogenic shock         â”‚
â”‚ â€¢ Age <75 years (relative)             â”‚
â”‚ â€¢ Potentially reversible condition     â”‚
â”‚ â€¢ Good baseline functional status      â”‚
â”‚                                         â”‚
â”‚ âŒ Exclusion criteria:                  â”‚
â”‚ â€¢ Irreversible multiorgan failure      â”‚
â”‚ â€¢ Active malignancy with poor prognosisâ”‚
â”‚ â€¢ Severe cognitive dysfunction         â”‚
â”‚ â€¢ Contraindication to anticoagulation  â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Current status documentation:        â”‚
â”‚ â€¢ Vasopressor requirements             â”‚
â”‚ â€¢ Cardiac function assessment          â”‚
â”‚ â€¢ Organ dysfunction evaluation         â”‚
â”‚                                         â”‚
â”‚ [Next: Mobile ECMO activation â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Cardiogenic Management]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 11A â€“ Mobile ECMO Activation (Node U â†’ V)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ MOBILE ECMO TEAM ACTIVATION          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš€ Transfer Center: 856-886-5111        â”‚
â”‚ Request: "Mobile ECMO consultation"     â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Information to provide:               â”‚
â”‚ â€¢ Patient demographics and history     â”‚
â”‚ â€¢ Current hemodynamic status           â”‚
â”‚ â€¢ Vasopressor/inotrope requirements    â”‚
â”‚ â€¢ Underlying cardiac condition         â”‚
â”‚                                         â”‚
â”‚ â±ï¸ Response timeline:                   â”‚
â”‚ â€¢ Phone consultation: <15 minutes      â”‚
â”‚ â€¢ Team mobilization: <60 minutes       â”‚
â”‚ â€¢ Bedside arrival: variable by locationâ”‚
â”‚                                         â”‚
â”‚ ğŸ› ï¸ Pre-arrival preparation:             â”‚
â”‚ â€¢ Continue maximal medical support     â”‚
â”‚ â€¢ Obtain ECMO consent                  â”‚
â”‚ â€¢ Prepare cannulation site             â”‚
â”‚                                         â”‚
â”‚ [Next: ECMO management â–¶]              â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: ECMO Evaluation]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 12A â€“ ICU Monitoring & Support (Node S - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ ICU MONITORING & ONGOING SUPPORT     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Hemodynamic monitoring:              â”‚
â”‚ â€¢ Arterial line for continuous BP      â”‚
â”‚ â€¢ Central venous pressure monitoring   â”‚
â”‚ â€¢ Cardiac output assessment            â”‚
â”‚ â€¢ Mixed venous oxygen saturation       â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Ongoing resuscitation goals:         â”‚
â”‚ â€¢ MAP â‰¥65 mmHg maintenance              â”‚
â”‚ â€¢ Urine output â‰¥0.5 mL/kg/hr           â”‚
â”‚ â€¢ Lactate clearance monitoring         â”‚
â”‚ â€¢ Hemoglobin >7 g/dL (>8 if cardiac)   â”‚
â”‚                                         â”‚
â”‚ ğŸ”„ Reassessment intervals:              â”‚
â”‚ â€¢ Vital signs q15min until stable      â”‚
â”‚ â€¢ Laboratory studies q4-6h             â”‚
â”‚ â€¢ Fluid balance q8h                    â”‚
â”‚ â€¢ Daily goals reassessment             â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Recovery planning:                   â”‚
â”‚ â€¢ Vasopressor weaning protocol         â”‚
â”‚ â€¢ Rehabilitation assessment            â”‚
â”‚ â€¢ Family communication                 â”‚
â”‚                                         â”‚
â”‚ âœ… ICU MONITORING PROTOCOL ACTIVE      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Treatment Pathways]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 12B â€“ ECMO Management (Node V - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ ECMO CANNULATION & MANAGEMENT        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ”§ Cannulation process:                 â”‚
â”‚ â€¢ Peripheral or central approach       â”‚
â”‚ â€¢ Ultrasound-guided vessel access      â”‚
â”‚ â€¢ Appropriate anticoagulation          â”‚
â”‚                                         â”‚
â”‚ âš™ï¸ ECMO parameters:                     â”‚
â”‚ â€¢ Blood flow: 60-80 mL/kg/min          â”‚
â”‚ â€¢ Sweep gas: 1-2 L/min initially       â”‚
â”‚ â€¢ Target oxygen saturation 88-95%      â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring requirements:             â”‚
â”‚ â€¢ Hemodynamic optimization             â”‚
â”‚ â€¢ Anticoagulation management           â”‚
â”‚ â€¢ Circuit monitoring and troubleshootingâ”‚
â”‚ â€¢ Daily weaning assessments            â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Recovery goals:                      â”‚
â”‚ â€¢ Myocardial recovery                  â”‚
â”‚ â€¢ Weaning from support                 â”‚
â”‚ â€¢ Neurologic preservation              â”‚
â”‚                                         â”‚
â”‚ âœ… ECMO PROTOCOL ACTIVE                â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Mobile ECMO Activation]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES HYPOTENSION & HEMORRHAGE ADDENDA

### **Enhanced RRT Response Program:**
- **Rapid Response Team:** Immediate multidisciplinary activation including critical care, surgery, anesthesia
- **Point-of-Care Ultrasound:** FAST exam capability on all RRT carts
- **Blood Bank Integration:** 24/7 MTP activation with <30 minute product delivery
- **Quality Metrics:** Time to IV access, fluid administration, blood product delivery

### **Massive Transfusion Protocol:**
**Activation Criteria:**
- **Anticipated:** >4 units PRBCs in 1 hour
- **Clinical:** Shock index >1.0 with ongoing bleeding
- **Laboratory:** Hemoglobin drop >2 g/dL with hypotension

**Product Ratios (1:1:1 preferred):**
- **PRBCs:** 6 units per pack
- **FFP:** 6 units per pack  
- **Platelets:** 1 apheresis unit (equivalent to 6 random donor)
- **Cryoprecipitate:** 10 units if fibrinogen <150 mg/dL

### **Hemostatic Agent Protocol:**
**Tranexamic Acid:**
- **Dose:** 1g IV over 10 minutes, then 1g over 8 hours
- **Timing:** Within 3 hours of bleeding onset
- **Contraindications:** Active thromboembolic disease

**Factor Concentrates:**
- **Prothrombin Complex Concentrate:** 25-50 units/kg for warfarin reversal
- **Fibrinogen Concentrate:** 3-4g IV if available instead of cryoprecipitate

### **Shock Classification & Management:**
**Distributive Shock:**
- **Hour-1 Bundle:** Lactate, blood cultures, antibiotics, fluid resuscitation
- **Vasopressors:** Norepinephrine first-line, vasopressin as adjunct
- **Source Control:** Aggressive evaluation and intervention

**Cardiogenic Shock:**
- **Inotropic Support:** Dobutamine or milrinone based on hemodynamics
- **Mechanical Support:** IABP, Impella, VA-ECMO based on severity
- **Coronary Evaluation:** Emergent catheterization if STEMI

### **Advanced Monitoring Capabilities:**
- **Arterial Lines:** Standard for vasopressor therapy
- **Central Venous Access:** Required for high-dose vasopressors and CVP monitoring
- **POCUS Integration:** FAST, cardiac function, IVC assessment
- **Advanced Hemodynamics:** Cardiac output monitoring available

### **Mobile ECMO Program:**
**Activation Criteria:**
- **Refractory cardiogenic shock** despite maximal medical therapy
- **Cardiac arrest** with ongoing CPR or recent ROSC
- **Bridge to recovery** or definitive intervention
- **Age <75 years** with good functional status

**Response System:**
- **24/7 Availability:** Through Transfer Center coordination
- **Response Time:** <60 minutes mobilization, transport time variable
- **Cannulation Options:** Peripheral or central approach based on anatomy
- **Transport Capability:** Ground and air medical compatibility

### **Quality Improvement Metrics:**
- **RRT Response Time:** Goal <15 minutes from activation
- **Time to IV Access:** Goal <5 minutes from arrival
- **MTP Activation:** Goal <15 minutes from recognition
- **Blood Product Delivery:** Goal <30 minutes from activation
- **ECMO Consultation:** Goal <15 minutes phone, <60 minutes mobilization

### **Special Population Considerations:**
**Anticoagulated Patients:**
- **Warfarin:** PCC 25-50 units/kg + vitamin K 10mg IV
- **Direct Oral Anticoagulants:** Specific reversal agents when available
- **Heparin:** Protamine sulfate 1mg per 100 units heparin

**Pregnant Patients:**
- **Modified resuscitation:** Left lateral displacement
- **Blood product goals:** Higher hemoglobin targets (>8-10 g/dL)
- **Obstetric consultation:** Immediate for pregnancy-related bleeding

### **Integration with Other Protocols:**
- **GI Bleeding Protocol:** Seamless transition for upper/lower GI sources
- **Anemia Management:** Coordinated transfusion thresholds
- **Shock & ECMO Protocol:** Advanced circulatory support pathways

## REFERENCE GUIDELINES
- **2022 Advanced Trauma Life Support (ATLS) Guidelines**
- **2023 ESAIC Guidelines on Management of Severe Perioperative Bleeding**
- **2021 Surviving Sepsis Campaign Guidelines**
- **Virtua Health System Hypotension & Hemorrhage Protocol v2025**

**This protocol integrates current evidence-based approaches to hypotension and hemorrhage management with advanced resuscitation capabilities and mechanical circulatory support options optimized for the Virtua Voorhees clinical environment.**
